Biotech Drug Report Generated Aug 1, 2026

AMT-162

QURE·uniQure N.V.

BEARISH

Drug Impact Rating1/10

Trial Phase: Phase 1/2 (discontinued)
Time to Market: Never — program discontinued in May 2026; no path to approval.
Why 1/10: No hard dated catalyst remains: AMT-162 development was discontinued on May 5, 2026 (announced with Q1 2026 results), so the defining binary has already resolved negatively and the program is a dead asset with no scheduled regulatory decision in the next ~12 months.

Actionable Insight ▼ BEARISH

AMT-162 is a closed chapter — uniQure (QURE) stopped the program in May 2026 after a dose-limiting toxicity and unfavorable preliminary data, so there is nothing to trade on this drug. QURE stock now trades purely on AMT-130 (Huntington's: UK MAA expected Q3 2026, FDA Type B meeting), AMT-260 and AMT-191, plus a ~10% dilutive June 2026 offering; watch those catalysts, not AMT-162.

Price Chart

Loading chart...

Executive Summary

AMT-162 (formerly Apic Bio's APB-102, licensed by uniQure in 2023) was a one-time, intrathecal AAVrh10 gene therapy for SOD1-ALS, an ultra-rare genetic form of ALS. It never got past a small Phase 1/2 trial (EPISOD1): after a positive first-cohort safety review (Jan 2025), enrollment was paused in 2025 following a dose-limiting toxicity, and uniQure officially discontinued development on May 5, 2026 after reviewing data from just five dosed patients. The program is now dead, and its already-small role in uniQure's value is zero; the stock (~$43.63 on 7/31/2026) is driven by the AMT-130 Huntington's program, with analysts still largely bullish (mean price target ~$65.5, strong-buy consensus) and cash of ~$586.6M funding operations into 2H 2029.

How It Works

A one-time gene therapy: a harmless engineered virus (AAVrh10) is injected into the spinal fluid and delivers a piece of genetic code (a microRNA) into cells, instructing them to destroy the messenger RNA of the SOD1 gene. That lowers levels of the faulty SOD1 protein that drives this rare inherited form of ALS.

Trial Status

The Phase 1/2 EPISOD1 open-label US trial (NCT06100276) dosed its first patient October 2024; an IDMC review in January 2025 found no significant safety concerns in the first cohort and cleared dose escalation. Enrollment was later voluntarily paused in 2025 after a serious adverse event judged a dose-limiting toxicity in one patient, and on May 5, 2026 uniQure announced it had discontinued AMT-162 after reviewing preliminary safety/efficacy data from the five patients dosed. Safety follow-up of those five patients continues.

The Two-Sided Case

▲ Bull Case3

Conceptually attractive: a one-time gene therapy that knocks down SOD1 protein could avoid the lifelong repeat lumbar-puncture dosing of the approved rival QALSODY (tofersen); the first EPISOD1 cohort cleared IDMC review in January 2025 with no significant safety concerns (biospace.com PR).

Negligible company-level damage: AMT-162 was a minor pipeline program and its discontinuation doesn't threaten uniQure's ~$586.6M cash position and runway into 2H 2029, so the drug's failure has little lasting impact on QURE's thesis (stocktitan Q1 2026 report).

Safety follow-up of the five dosed patients continues, so data from the program may still inform uniQure's AAV delivery platform and future vector designs (adisinsight.springer.com trial note).

▼ Bear Case4

Development is discontinued (announced May 5, 2026): a serious adverse event judged a dose-limiting toxicity plus unfavorable preliminary efficacy/safety data from the five-patient EPISOD1 trial ended the program, so AMT-162 has no future commercial value (precisionmedicineonline.com; uniqure.gcs-web.com Q1 2026 release).

Competition was already entrenched: Biogen/Ionis' QALSODY (tofersen) won FDA accelerated approval for SOD1-ALS in April 2023 (first approved therapy targeting a genetic cause of ALS) and EU approval, setting a high bar for a Phase 1/2 gene therapy (investors.biogen.com).

Tiny, safety-hobbled dataset: only five patients were ever dosed, and the dose-limiting toxicity highlights real safety risk of high-dose intrathecal AAV delivery; the pipeline page itself confirms enrollment was paused after the SAE (uniqure.com).

For QURE shareholders the drug is dead weight, and the broader stock is dealing with its own pressures (widening Q1 2026 net loss to $53.5M and a ~$225M dilutive June 2026 offering) unrelated to AMT-162.

Upcoming Catalysts

None for AMT-162 — program discontinued; only ongoing safety follow-up of five dosed patients
QURE-level catalysts to watch instead: UK MAA filing for AMT-130 expected Q3 2026, FDA Type B meeting on AMT-130 trial design, AMT-260 first-cohort data (due ~June 2026 per Q1 report), AMT-191 updates

Source Filing

The SecBot filing or press-release report that triggered this drug report:

uniQure N.V. 8-K QURE ·Originating report

Sources · 13

Hover a chip for the title

1 uniqure.com2 uniqure.gcs-web.com3 clinicaltrials.gov4 precisionmedicineonline.com5 als.be6 uniqure.gcs-web.com7 biospace.com8 investors.biogen.com9 synapse.patsnap.com10 adisinsight.springer.com11 alsnewstoday.com12 tipranks.com13 stocktitan.net